Letai A - Search Results

1

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Letai A, et al. Cancer Cell. 2002 Sep;2(3):183-92. doi: 10.1016/s1535-6108(02)00127-7. Cancer Cell. 2002. PMID: 12242151 Free article.

2

BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.

Letai A. Letai A. Expert Opin Biol Ther. 2003 Apr;3(2):293-304. doi: 10.1517/14712598.3.2.293. Expert Opin Biol Ther. 2003. PMID: 12662143

3

Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Opferman JT, et al. Among authors: letai a. Nature. 2003 Dec 11;426(6967):671-6. doi: 10.1038/nature02067. Nature. 2003. PMID: 14668867 Free article.

4

Antiapoptotic BCL-2 is required for maintenance of a model leukemia.

Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Letai A, et al. Cancer Cell. 2004 Sep;6(3):241-9. doi: 10.1016/j.ccr.2004.07.011. Cancer Cell. 2004. PMID: 15380515 Free article.

5

An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. Oltersdorf T, et al. Among authors: letai a. Nature. 2005 Jun 2;435(7042):677-81. doi: 10.1038/nature03579. Epub 2005 May 15. Nature. 2005. PMID: 15902208 Free article.

6

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC. Chauhan D, et al. Among authors: letai a. Cancer Cell. 2005 Nov;8(5):407-19. doi: 10.1016/j.ccr.2005.10.013. Cancer Cell. 2005. PMID: 16286248 Free article.

7

Growth factor withdrawal and apoptosis: the middle game.

Letai A. Letai A. Mol Cell. 2006 Mar 17;21(6):728-30. doi: 10.1016/j.molcel.2006.03.005. Mol Cell. 2006. PMID: 16543140 Free article. Review.

8

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Certo M, et al. Among authors: letai a. Cancer Cell. 2006 May;9(5):351-65. doi: 10.1016/j.ccr.2006.03.027. Cancer Cell. 2006. PMID: 16697956 Free article.

9

Restoring cancer's death sentence.

Letai A. Letai A. Cancer Cell. 2006 Nov;10(5):343-5. doi: 10.1016/j.ccr.2006.10.014. Cancer Cell. 2006. PMID: 17097553 Free article.

10

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Del Gaizo Moore V, et al. Among authors: letai a. J Clin Invest. 2007 Jan;117(1):112-21. doi: 10.1172/JCI28281. J Clin Invest. 2007. PMID: 17200714 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

212 results

Search Page

Filters